This up-to-date roundup presents the 7 clinical-stage gene-editing approaches to sickle cell disease, which affects millions of people worldwide and...

On Monday, Beam Therapeutics announced that the U.S. FDA had cleared BEAM-101 for clinical evaluation as a treatment for sickle cell disease. BEAM-101...

This week, we look at a CRISPR-based therapy for HIV that has just passed the IND approval stage, and will soon be tested in a Phase 1/2 clinical...

This week’s clinical update looks at a Phase 1 trial for ET-01, a CRISPR-edited blood cell therapy for beta-thalassemia.

CRISPR-based blood cell therapies are advancing through clinical trials, with promising results stacking up for certain rare genetic diseases and some...

In this week’s update, we present a CRISPR-based therapy for sickle cell disease (SCD) that has moved from the investigational new drug (IND) stage...

A new generation of therapies based on CRISPR-Cas and other gene-editing technologies brings hope to the millions of people living with a rare genetic...